This is Archived Content

This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA).
View current meetings on


March 22, 2016 - 8:28am to March 23, 2016 - 8:29am
NIH Campus, Bethesda, MD


Catilin Dudevoir

Agenda and Video Links

Day 1: March 22, 2016

9:00 – 9:30 a.m. Welcome and National Institutes of Health (NIH) Director Remarks - [ Video, 20 mins ]
Nora D. Volkow, M.D., Director, NIDA
Walter J. Koroshetz, M.D., Director, NINDS
9:30 – 11:00 a.m.

Understanding the Endocannabinoid System - [ Video, 1:29:11 ]

David Shurtleff, Ph.D. - NCCIH
Aidan Hampson, Ph.D. - NIDA

The Endocannabinoid System – An Introduction
Benjamin Cravatt, Ph.D. - The Scripps Research Institute

Cannabinoid Receptors: Where They Are and What They Do
Ken Mackie, M.D. – Indiana University

Therapeutic Potential of the Cannabinoid System
Daniele Piomelli, Ph.D. – University of California, Irvine

11:15 – 12:45 p.m.

Brain Development and Function - [ Video, 1:22:08 ]

Steve Grant, Ph.D. - NIDA

Does Marijuana Harm The Brain?
Kent Hutchison, Ph.D. - University of Colorado Boulder

Brain Development and Function: Adolescent Marijuana use: Influence on Learning, Memory and Brain Changes
Susan Tapert, Ph.D. - University of California, San Diego

Cannabis Use and Cognitive Impairment
Madeline Meier, Ph.D. - Arizona State University

2:00 – 2:15 p.m.

Office of National Drug Control Policy Remarks - [ Video, 20:27 ]
Michael Botticelli, Director of National Drug Control Policy, ONDCP

Summit Host Remarks
Peggy Murray, Ph.D. - NIAAA

2:15 – 3:45 p.m.

Psychosis, Addiction, and Alcohol Interactions - [ Video, 1:26:10 ]

David Goldman, M.D. - NIAAA
Wilson M. Compton, M.D., M.P.E. - NIDA

The Association Between Cannabis Use and Psychosis: Clinical, Epidemiological, and Neuroscience Perspectives
Anne Eden Evins, M.D., M.P.H. - Massachusetts General Hospital

Addiction to Cannabis Phenomenology, Prevalence, Outcomes & Probability
Alan Budney, Ph.D. - Geisel School of Medicine at Dartmouth

Marijuana and Alcohol Interactions: Co-morbidity, Consequences and Mechanisms
Larry Parsons, Ph.D. - The Scripps Research Institute

4:00 – 5:30 p.m.

Therapeutic Potential: Epilepsy and Multiple Sclerosis - [ Video, 1:26:04 ]

Alan L. Willard, Ph.D. - NINDS

Mechanisms of Cannabinoid Signaling in Epilepsy
Ivan Soltesz, Ph.D. - Stanford University

Cannabinoids for Treatment of Pediatric Epilepsy: The Hype and the Evidence
Amy Brooks-Kayal, M.D. - Children’s Hospital Colorado

Multiple Sclerosis and Cannabinoids: Therapeutic Potential
David Gloss, M.D., M.P.H. - Charleston Area Medical Center

Day 2: March 23, 2016

9:00 – 9:15 a.m. Welcome and NIH Director Remarks - [ Video, 17:04 ]

Nora D. Volkow, M.D., Director - NIDA
Francis S. Collins, M.D., Ph.D., Director, NIH
9:15 – 9:45 a.m.

Psychomotor Performance and Detection - [ Video, 38:06 ]

Steve Gust, Ph.D. - NIDA

Effects of Cannabis on Human Psychomotor Performance
Marilyn Huestis, Ph.D. - University of Maryland School of Medicine

9:45 – 11:45 a.m.

Therapeutic Potential: Pain and PTSD/Anxiety - [ Video, 1:54:25 ]

John Williamson, Ph.D. - NCCIH
Susan Borja, Ph.D. - NIMH

Harnessing the Therapeutic Potential of the Endocannabinoid Signaling System to Suppress Pain
Andrea G. Hohmann, Ph.D. - Indiana University

The Therapeutic Potential of Cannabis in the Treatment of Neuropathic Pain
Barth Wilsey, M.D. - University of California, San Diego

Cannabinoids and the Processing of Fear and Anxiety: Preclinical Studies
Cecilia Hillard, Ph.D. - Medical College of Wisconsin

What is the Therapeutic Potential of Cannabis in PTSD & Anxiety Disorder Treatment?: Evidence from Human Studies
Christine Rabinak, Ph.D. - Wayne State University

1:00 – 1:15 p.m. Summit Host Remarks - [ Video, 10:43 ]

Bruce Cuthbert, Ph.D., Acting Director, NIMH
Josephine P. Briggs, M.D., Director, NCCIH
1:15 – 3:15 p.m.

Policy Research: Challenges and Future Directions - [ Video, 2:02:55 ]

Susan Weiss, Ph.D. - NIDA
Michael Hilton, Ph.D. - NIAAA

A Cannabis Research Agenda for Policy Design: What Do We Need to Know?
Mark Kleiman, Ph.D., M.P.P. - NYU Marron Institute of Urban Management
BOTEC Analysis Corporation

The Effects of Liberalizing Marijuana Policies on Use & Harms: Why Research Has Not Told Us Much
Rosalie Liccardo Pacula, Ph.D. - RAND Corporation

Regulating Retail Marijuana: Lessons Learned from Tobacco Control
Stanton Glantz, Ph.D. - University of California, San Francisco

Policy Surveillance Resources
Rosalie Liccardo Pacula, Ph.D. - RAND Corporation

Recreational Use of Cannabis to be Included in Alcohol Policy Information System
Michael Hilton, Ph.D. - NIAAA

3:15 – 4:00 p.m. Concluding Remarks - [ Video, 29:22 ]

Robert M. Califf, M.D., Commissioner of Food and Drugs, FDA
Nora D. Volkow, M.D., Director, NIDA

Photographs/images from the meeting are available on NIDA's Flickr page

Background Information

Marijuana and Cannabinoids: A Neuroscience Research Summit is being convened by the National Institutes of Health (NIH), which will focus on the neurological and psychiatric effects of marijuana, other cannabinoids, and the endocannabinoid system. Both the adverse and the potential therapeutic effects of the cannabinoid system will be discussed. The goal of this summit is to ensure evidence-based information is available to inform practice and policy, particularly important at this time given the rapidly shifting landscape regarding the recreational and medicinal use of marijuana. The meeting is being sponsored by several NIH Institutes and Centers: the National Institute on Drug Abuse (NIDA); the National Institute on Alcohol Abuse and Alcoholism (NIAAA); the National Center for Complementary and Integrative Health (NCCIH); the National Institute of Mental Health (NIMH); and the National Institute of Neurological Disorders and Stroke (NINDS). The event will be held on March 22-23 at the Natcher Conference Center on the NIH campus in Bethesda, Maryland. .

NOTE: Some data presented at the Summit may be embargoed. Please contact speakers directly for permission to use data.